X0306 4 2021-08-16 0 0001490978 Schrodinger, Inc. SDGR 0001797672 Akinsanya Karen C/O SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR NEW YORK NY 10036 0 1 0 0 See Remarks Common Stock 2021-08-16 4 M 0 20181 17.00 A 20181 D Common Stock 2021-08-16 4 M 0 4180 4.34 A 24361 D Common Stock 2021-08-16 4 M 0 13377 3.22 A 37738 D Common Stock 2021-08-16 4 S 0 21691 57.4334 D 16047 D Common Stock 2021-08-16 4 S 0 16047 58.1745 D 0 D Stock Option (right to buy) 17.00 2021-08-16 4 M 0 20181 0.00 D 2030-02-05 Common Stock 20181 180478 D Stock Option (right to buy) 4.34 2021-08-16 4 M 0 4180 0.00 D 2028-11-29 Common Stock 4180 45985 D Stock Option (right to buy) 3.22 2021-08-16 4 M 0 13377 0.00 D 2028-08-03 Common Stock 13377 13378 D These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.90 to $57.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.905 to $58.86, inclusive. This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024. This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022. The option was granted on August 3, 2018. The shares underlying the option are scheduled to vest in equal yearly installments from May 14, 2018 through May 14, 2022. EVP, Chief Biomedical Scientist, Head of Discovery R&D /s/ Donald Shum, as attorney-in-fact for Karen Akinsanya 2021-08-17